{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T23:03:25Z","timestamp":1777417405210,"version":"3.51.4"},"reference-count":64,"publisher":"SAGE Publications","issue":"5","license":[{"start":{"date-parts":[[2001,5,1]],"date-time":"2001-05-01T00:00:00Z","timestamp":988675200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Ann Pharmacother"],"published-print":{"date-parts":[[2001,5]]},"abstract":"<jats:sec>\n                    <jats:title>OBJECTIVE:<\/jats:title>\n                    <jats:p>To provide a comprehensive review of linezolid, the first of a new class of antibiotics, the oxazolidinones. Therapeutic issues regarding the emergence of multidrug-resistant bacteria and a brief history of the oxazolidinones are also discussed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>DATA SOURCES:<\/jats:title>\n                    <jats:p>A MEDLINE search (1966\u2013March 2001) was conducted to identify pertinent literature, including preclinical trials, clinical trials, and reviews. Unpublished clinical data, adverse effects, and dosing information were abstracted from product labeling.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>STUDY SELECTION:<\/jats:title>\n                    <jats:p>Clinical efficacy data were extracted from clinical trials, case reports, and abstracts that mentioned linezolid. Additional information concerning antibiotic resistance, the oxazolidinones, in vitro susceptibility, and the pharmacokinetic profile of linezolid also was reviewed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>DATA SYNTHESIS:<\/jats:title>\n                    <jats:p>Linezolid exhibits activity against many gram-positive organisms, including vancomycin-resistant Enterococcus faecium, methicillin-resistant Staphylococcus aureus, and penicillin-resistant Streptococcus pneumoniae. Linezolid inhibits bacterial protein synthesis at an early step in translation and is rapidly and completely absorbed from the gastrointestinal tract following oral administration. Efficacy has been demonstrated in a number of unpublished clinical trials in adults with pneumonia, skin and skin structure infections, and vancomycin-resistant E. faeciuminfections. The adverse effect profile is similar to that of comparator agents (\u03b2-lactams, clarithromycin, vancomycin).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSIONS:<\/jats:title>\n                    <jats:p>Linezolid is the first oral antimicrobial agent approved for the treatment of vancomycin-resistant enterococci. Since the oxazolidinones have a unique mechanism of action and expanded spectrum of activity against virulent and highly resistant gram-positive pathogens, linezolid is a valuable alternative to currently available treatment options. Clinical trials evaluating linezolid and other oxazolidinones for antibiotic-resistant gram-positive infections, as well as comparator studies comparing linezolid with other candidate drugs, such as quinupristin\/dalfopristin and chloramphenicol, will further define the role of linezolid.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1345\/aph.10276","type":"journal-article","created":{"date-parts":[[2003,6,3]],"date-time":"2003-06-03T17:09:55Z","timestamp":1054660195000},"page":"566-575","source":"Crossref","is-referenced-by-count":54,"title":["Linezolid for the Treatment of Resistant Gram-Positive Cocci"],"prefix":"10.1177","volume":"35","author":[{"given":"Kevin T","family":"Bain","sequence":"first","affiliation":[{"name":"Kevin T Bain PharmD, at time of writing, Clinical Pharmacist, Specialized Pharmacy Services, Thomas Jefferson University, Philadelphia, PA; now, Staff Pharmacist, CVS\/Pharmacy, Philadelphia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric T","family":"Wittbrodt","sequence":"additional","affiliation":[{"name":"Eric T Wittbrodt PharmD BCPS, Associate Professor of Clinical Pharmacy, Philadelphia College of Pharmacy, University of the Sciences in Philadelphia, Philadelphia, PA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2001,5,1]]},"reference":[{"key":"bibr1-aph.10276","first-page":"435","volume":"16","author":"Ford CW","journal-title":"Infect Med"},{"key":"bibr2-aph.10276","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/42.6.721"},{"key":"bibr3-aph.10276","doi-asserted-by":"publisher","DOI":"10.1016\/S0732-8893(98)00108-4"},{"key":"bibr4-aph.10276","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/43.4.569"},{"key":"bibr5-aph.10276","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.43.8.2059"},{"key":"bibr6-aph.10276","doi-asserted-by":"publisher","DOI":"10.1016\/S0891-5520(05)70388-3"},{"key":"bibr7-aph.10276","doi-asserted-by":"publisher","DOI":"10.1016\/S0732-8893(97)00115-6"},{"key":"bibr8-aph.10276","doi-asserted-by":"publisher","DOI":"10.1016\/S0732-8893(97)00212-5"},{"key":"bibr9-aph.10276","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.42.7.1762"},{"key":"bibr10-aph.10276","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200003093421007"},{"key":"bibr11-aph.10276","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.42.6.1520"},{"key":"bibr12-aph.10276","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.40.3.799"},{"key":"bibr13-aph.10276","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.40.4.839"},{"key":"bibr14-aph.10276","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199907223410403"},{"key":"bibr15-aph.10276","doi-asserted-by":"publisher","DOI":"10.1016\/S0732-8893(97)00210-1"},{"key":"bibr16-aph.10276","doi-asserted-by":"publisher","DOI":"10.1016\/S0732-8893(98)00148-5"},{"key":"bibr17-aph.10276","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.40.7.1745"},{"key":"bibr18-aph.10276","doi-asserted-by":"publisher","DOI":"10.1093\/clind\/24.4.584"},{"key":"bibr19-aph.10276","doi-asserted-by":"publisher","DOI":"10.1016\/S0732-8893(99)00016-4"},{"key":"bibr20-aph.10276","first-page":"597","volume":"42","year":"1993","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"bibr21-aph.10276","doi-asserted-by":"publisher","DOI":"10.1086\/313597"},{"key":"bibr22-aph.10276","doi-asserted-by":"publisher","DOI":"10.1086\/515002"},{"key":"bibr23-aph.10276","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9343(98)00152-1"},{"key":"bibr24-aph.10276","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.37.10.2119"},{"key":"bibr25-aph.10276","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.42.10.2710"},{"key":"bibr26-aph.10276","first-page":"1035","volume":"27","author":"Wood CA","year":"1998","journal-title":"Clin Infect Dis"},{"key":"bibr27-aph.10276","first-page":"1035","volume":"27","author":"Wood CA","year":"1998","journal-title":"Clin Infect Dis"},{"key":"bibr28-aph.10276","first-page":"1035","volume":"27","author":"Mandler HD","year":"1998","journal-title":"Clin Infect Dis"},{"key":"bibr29-aph.10276","doi-asserted-by":"publisher","DOI":"10.1093\/clinids\/24.1.90"},{"key":"bibr30-aph.10276","doi-asserted-by":"publisher","DOI":"10.1086\/520289"},{"key":"bibr31-aph.10276","doi-asserted-by":"publisher","DOI":"10.1016\/0732-8893(89)90108-9"},{"key":"bibr32-aph.10276","doi-asserted-by":"publisher","DOI":"10.2307\/30148460"},{"key":"bibr33-aph.10276","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.43.2.421"},{"key":"bibr34-aph.10276","first-page":"813","volume":"46","year":"1997","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"bibr35-aph.10276","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/43.1.31"},{"key":"bibr36-aph.10276","doi-asserted-by":"publisher","DOI":"10.1378\/chest.115.suppl_1.14S"},{"key":"bibr37-aph.10276","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.160.10.1399"},{"key":"bibr38-aph.10276","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.31.11.1791"},{"key":"bibr39-aph.10276","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.40.3.720"},{"key":"bibr40-aph.10276","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.32.9.1341"},{"key":"bibr41-aph.10276","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.40.6.1508"},{"key":"bibr42-aph.10276","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/21.6.711"},{"key":"bibr43-aph.10276","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/21.6.721"},{"key":"bibr44-aph.10276","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.32.8.1218"},{"key":"bibr45-aph.10276","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.41.10.2132"},{"key":"bibr46-aph.10276","doi-asserted-by":"publisher","DOI":"10.1016\/0006-291X(88)90723-1"},{"key":"bibr47-aph.10276","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.42.12.3251"},{"key":"bibr48-aph.10276","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.41.10.2127"},{"key":"bibr49-aph.10276","volume-title":"Linezolid (Zyvox)","year":"2000"},{"key":"bibr50-aph.10276","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.42.3.721"},{"key":"bibr51-aph.10276","doi-asserted-by":"publisher","DOI":"10.1002\/j.1875-9114.1998.tb03109.x"},{"key":"bibr52-aph.10276","unstructured":"Stalker DJ, Wajszczuk CP, Batts DH. Linezolid safety, tolerance, and pharmacokinetics following oral dosing twice daily for 14.5 days (abstract A115). In: Programs and Abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); Toronto, Ontario, Canada, September 28\u2013October 1, 1997."},{"key":"bibr53-aph.10276","unstructured":"Stalker DJ, Wajszczuk C P, Batts DH. Linezolid safety, tolerance, and pharmacokinetics after intravenous dosing twice daily for 7.5 days (abstract A116). In: Programs and Abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); Toronto, Ontario, Canada, September 28\u2013October 1, 1997."},{"key":"bibr54-aph.10276","first-page":"1000","volume":"29","author":"Graham CS","year":"1999","journal-title":"Clin Infect Dis"},{"key":"bibr55-aph.10276","unstructured":"Birmingham MC, Zimmer GS, Flavin SM, Rayner CR, Welch KE, Smith PF,  Results of treating bacteremic patients with linezolid in a compassionate use trial for resistant, gram-positive infection (poster 129). Proceedings of the 37th Annual Meeting of the Infectious Diseases Society of America (IDSA); Philadelphia, November 18\u201321, 1999."},{"key":"bibr56-aph.10276","unstructured":"Noskin GA, Siddiqui F, Stosor V, Peterson LR. Linezolid (LZD) for the treatment of vancomycin-resistant enterococci (VRE) in immunocom-promised hosts (poster 133). Proceedings of the 37th Annual Meeting of the Infectious Diseases Society of America (IDSA); Philadelphia, November 18\u201321, 1999."},{"key":"bibr57-aph.10276","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1086\/520485","volume":"29","author":"Smith PF","year":"1999","journal-title":"Clin Infect Dis"},{"key":"bibr58-aph.10276","first-page":"987","volume":"29","author":"Husni RI","year":"1999","journal-title":"Clin Infect Dis"},{"key":"bibr59-aph.10276","doi-asserted-by":"publisher","DOI":"10.1086\/517221"},{"key":"bibr60-aph.10276","doi-asserted-by":"publisher","DOI":"10.1086\/313669"},{"key":"bibr61-aph.10276","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200059040-00007"},{"key":"bibr62-aph.10276","doi-asserted-by":"publisher","DOI":"10.1097\/00004714-199610000-00007"},{"key":"bibr63-aph.10276","first-page":"1481","volume":"57","year":"2000","journal-title":"AHFS firstFAX\u2122."},{"key":"bibr64-aph.10276","volume-title":"2000 Drug topics red book","author":"Sifton DW","year":"2000"}],"container-title":["Annals of Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1345\/aph.10276","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1345\/aph.10276","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T11:04:42Z","timestamp":1777374282000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1345\/aph.10276"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,5]]},"references-count":64,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2001,5]]}},"alternative-id":["10.1345\/aph.10276"],"URL":"https:\/\/doi.org\/10.1345\/aph.10276","relation":{},"ISSN":["1060-0280","1542-6270"],"issn-type":[{"value":"1060-0280","type":"print"},{"value":"1542-6270","type":"electronic"}],"subject":[],"published":{"date-parts":[[2001,5]]}}}